Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term rollover safety study of osilodrostat in endogenous Cushing syndrome
NL-OMON55862Phase 2Active, not recruiting
- Sponsor
- Recordati SpA
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osilodrostat in endogenous Cushing's syndrome and Cushing's syndrome, sponsored by Recordati SpA. Primary endpoint: Long-term safety. Started Nov 2019; status: active, not recruiting.
02
Drugs
osilodrostat
03
Conditions
endogenous Cushing's syndromeCushing's syndrome
Beyond the preview
Go deeper on NL-OMON55862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55862.